Melanoma pp 313-322 | Cite as

Current Surgical Management of Primary Cutaneous Melanoma

  • Adam I. RikerEmail author
  • Marco Antonio Rajo
  • Stephen L. Lambert
  • Jonathan S. Lam


The surgical management of melanoma has dramatically changed over the last few decades. Through the development and conduction of well-designed prospective, randomized trials, we have been able to refine the way that we surgically manage patients with melanoma. Indeed, many important issues have been addressed through such trials: the proper surgical margins for the primary melanoma, utility of the elective lymph node dissection, and the role for selective lymphadenectomy, to name a few. In this review, we will provide an overview of the current literature and offer practice guidelines for the surgical management of the primary melanoma.


Melanoma Sentinel node Lymphoscintigraphy Complete lymph node dissection Isolated limb perfusion Multidisciplinary cancer care Surgical management Cytoreductive surgery 



Complete lymph node dissection


Elective lymph node dissection


National Comprehensive Care Network


Positron emission tomography


Sentinel lymph node(s)


Sentinel lymph node biopsy


  1. 1.
    Urteaga OB, Pack GT. On the antiquity of melanoma. Cancer. 1967;19:607–10.CrossRefGoogle Scholar
  2. 2.
    Home Sir Everhard. Observations on cancer. London. 48 (1805).Google Scholar
  3. 3.
    Laennec RTH. Sur les melanoses. Bull Fac Med Paris. 1812;1:2.Google Scholar
  4. 4.
    Norris W. Case of fungoid disease. Edinburgh Med Surg J. 1820;16:562.Google Scholar
  5. 5.
    Norris W. Eight cases of melanosis with pathological and therapeutical remarks on that disease. London: Longman, Brown, Green, Longman and Roberts; 1857.Google Scholar
  6. 6.
    Parrish I. Case of melanosis. Am J Med Sci. 1837;20:266.Google Scholar
  7. 7.
    Cooper S. The first lines of the theory and practice of surgery. London: Longman; 1840.Google Scholar
  8. 8.
    Pemberton O. Observations on the history, pathology and treatment of cancerous diseases. London: Churchill J; 1858.Google Scholar
  9. 9.
    Snow H. Melanotic cancerous disease. Lancet. 1892;2:872–4.Google Scholar
  10. 10.
    Eve F. Lecture on melanoma. Practitioner. 1903;70:165.Google Scholar
  11. 11.
    Handley WS. The pathology of melanotic growths in relation to their operative treatment (II). Lancet. 1907;1:996–1001.Google Scholar
  12. 12.
    Clark WH Jr, From L, Bernardino EA, Mihm MC Jr. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–27.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Breslow A, Cascinelli N, van der Esch EP, Morabito A. Stage I melanoma of the limbs: assessment of prognosis by levels of invasion and maximum thickness. Tumori. 1978;64:273–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Fee HJ, Robinson DS, Sample WF, et al. The determination of lymph shed by colloidal gold scanning patients with malignant melanoma: a preliminary study. Surgery. 1987;84:626–32.Google Scholar
  16. 16.
    Morton D, Cagle L, Wong J, et al. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure for clinical stage I melanoma. Presented at the Annual Meeting of the Society of Surgical Oncology; Washington, DC. 1990.Google Scholar
  17. 17.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.CrossRefPubMedGoogle Scholar
  19. 19.
    Salopek TG, Slade J, Marghoob AA, et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. I. Survey of biopsy practices of pigmented lesions suspected as melanoma. J Am Acad Dermatol. 1995;33:441–50.CrossRefPubMedGoogle Scholar
  20. 20.
    Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol. 2001;54:260–76.CrossRefGoogle Scholar
  21. 21.
    Thomas L, Tranchard P, Berard F, Secchi T, Colin C, Moulin G. Semiological value of ABCD criteria in the diagnosis of cutaneous pigmented tumors. Dermatology. 1998;197:11–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Weinstock MA. Early detection of melanoma. JAMA. 2000;284:886–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Nachbar F, Soltz W, Merkle T, et al. The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. J Am Acad Dermatol. 1994;30:551–9.CrossRefPubMedGoogle Scholar
  24. 24.
    McGovern TW, Litaker MS. Clinical predictors of malignant pigmented lesions. A comparison of the Glasgow seven-point checklist and the American Cancer Society’s ABCD of pigmented lesions. J Dermatol Surg Oncol. 1992;18:22–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Argenziano G, Soyer H. Dermoscopy of pigmented skin lesions—a valuable toll for early diagnosis of melanoma. Lancet Oncol. 2001;2:443–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Argenziano G, Fabbrocini G, Carli P, DeGiogi V, Sammarco E, Delfino M. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol. 1998;134:1563–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Breslow A. Prognostic factors in the treatment of cutaneous melanoma. J Cutan Pathol. 1979;6:208–12.CrossRefPubMedGoogle Scholar
  28. 28.
    Clark WH Jr, Elder DE, Guerry DT, et al. Model predicting survival instage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893–904.CrossRefPubMedGoogle Scholar
  29. 29.
    Farmer ER. Why a skin biopsy? Arch Dermatol. 2000;136:779–80.CrossRefPubMedGoogle Scholar
  30. 30.
    Herlyn M, Ferrone S, Ronai Z, Finerty J, Pelroy R, Mohla S. Melanoma biology and progression. Cancer Res. 2001;61:4642–3.PubMedGoogle Scholar
  31. 31.
    Johnson TM, Sondak VK. Melanoma margins: the importance and need for more evidence-based trials. N Engl J Med. 2004;350:757–66.CrossRefGoogle Scholar
  32. 32.
    Landthaler M, Braun-Falco O, Leitl A, Konz B, Holzel D. Excisional biopsy as the first therapeutic procedure versus primary wide local excision of malignant melanoma. Cancer. 1989;64:1612–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Levi F, Randimbison L, LaVecchia C, Te VC, Frandeschi S. Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int J Cancer. 1998;78:315–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Macy-Roberts E, Ackerman AB. A critique of techniques for biopsy of clinically suspected malignant melanomas. Am J Dermatopathol. 1982;4:391–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Riker AI, Glass F, Perez I, Cruse CW, Messina J, Sondak VK. Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther. 2005;18:387–93.CrossRefPubMedGoogle Scholar
  36. 36.
    Roses D. Biopsy technique for suspected melanoma. Pigment Cell. 1985;7:8–17.Google Scholar
  37. 37.
    Amin MB, Edge S, Greene F, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2016. p. 563–85.Google Scholar
  38. 38.
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2001;88:3635–48.Google Scholar
  39. 39.
    Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients. Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.CrossRefPubMedGoogle Scholar
  40. 40.
    Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1–4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218(3):262–7.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Balch CM, Soong SJ, Ross MI, et al. Long term results of a prospective trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol. 2001;8:101–8.PubMedGoogle Scholar
  42. 42.
    Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2mm: a randomised, multicenter trial. Lancet. 2011;378:1635–42.CrossRefPubMedGoogle Scholar
  43. 43.
    Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1 mm thick). Cancer. 2003;97:1941–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2 cm versus 5 cm resection margins for patients with cutaneous melanoma with a thickness of 0.8 to 2.0 mm. Cancer. 2000;89:1495–501.CrossRefPubMedGoogle Scholar
  45. 45.
    Tanabe KK, Reintgen DS, Balch CM. Local recurrences and their management. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, editors. Cutaneous melanoma. 4th ed. St. Louis, MI: Quality Medical Publishing; 2003. p. 263–73.Google Scholar
  46. 46.
    Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;322:1159–62.CrossRefGoogle Scholar
  47. 47.
    Santinarni M, Maurici A, Patuzzo R, et al. Impact of clinical trials on the treatment of melanoma. Surg Oncol Clin N Am. 2001;10:935–47.CrossRefGoogle Scholar
  48. 48.
    Hudson LE, Maithel SK, Carlson GW, et al. 1 or 2 cm margins of excision for T2 melanomas: do they impact recurrence or survival? Ann Surg Oncol. 2013;20:346–51.CrossRefPubMedGoogle Scholar
  49. 49.
    Doepker MP, Thompson ZJ, Fisher KJ, Yamamoto M, Nethers KW, Harb JN, Applebaum MA, Gonzalez RJ, Sarnaik AA, Messina JL, et al. Is a wider margin (2cm vs. 1 cm) for a 1.01-2.0 mm melanoma necessary? Ann Surg Oncol. 2016;23(7):2336–42.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757–66.CrossRefPubMedGoogle Scholar
  51. 51.
    Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol. 1998;5:322–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Kenady DE, Brown BW, McBride CM. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. Surgery. 1982;92(4):615–8.PubMedGoogle Scholar
  53. 53.
    Sondergaard K, Schou G. Therapeutic and clinico-pathological factors in the survival of 1,469 patients with primary cutaneous malignant melanoma in clinical stage I. A multivariate regression analysis. Virchows Arch A Pathol Anat Histopathol. 1985;408(2-3):249–58.CrossRefPubMedGoogle Scholar
  54. 54.
    Corsten M, Johnson-Obaseki S. Sentinal lymph node biopsy in head and neck melanoma: a review. J Patient-Centered Res Rev. 2014;1(1):27–32.CrossRefGoogle Scholar
  55. 55.
    Cruse CW, Wells KE, Reintgen DS. Treatment of the primary in malignant melanoma of the skin. Ann Plast Surg. 1992;28:22–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Cochran AM, Buchanan PJ, Bueno RA Jr, et al. Subungual melanoma: a review of current treatment. Plast Reconstr Surg. 2014;134(2):259–73.CrossRefPubMedGoogle Scholar
  57. 57.
    Haddock NT, Wilson SC, Shapiro RL, et al. Wide local en bloc excision of subungual melanoma in situ. Ann Plast Surg. 2014;73(6):640–4.CrossRefPubMedGoogle Scholar
  58. 58.
    Nakamura Y, Ohara K, Kishi A, et al. Effects of non-amputative wide local excision on the local control and prognosis of in situ and invasive subungual melanoma. J Dermatol. 2015;42(9):861–6.CrossRefPubMedGoogle Scholar
  59. 59.
    Anda-Juarez MC, Martinez-Velasco MA, Fonte-Avalos V, et al. Conservative surgical management of in situ subungual melanoma: long-term follow-up. An Bras Dermatol. 2016;91(6):846–8.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma, version 1.2017. National Comprehensive Cancer Network, Fort Washington, PA. 2016.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Adam I. Riker
    • 1
    Email author
  • Marco Antonio Rajo
    • 1
  • Stephen L. Lambert
    • 2
  • Jonathan S. Lam
    • 1
  1. 1.Section of Surgical Oncology, Department of Surgery, School of MedicineLouisiana State UniversityNew OrleansUSA
  2. 2.Department of Family Medicine, Health Science CenterLouisiana State UniversityNew OrleansUSA

Personalised recommendations